|
|
Volumn 351, Issue , 2015, Pages
|
|
No correction, no retraction, no apology, no comment: Paroxetine trial reanalysis raises questions about institutional responsibility
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IMIPRAMINE;
PAROXETINE;
PLACEBO;
ANTIDEPRESSANT AGENT;
ARTICLE;
CONFLICT OF INTEREST;
DEPRESSION;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG LABELING;
DRUG MARKETING;
DRUG SAFETY;
DRUG TOLERABILITY;
HEALTH CARE ORGANIZATION;
HUMAN;
LAW SUIT;
MEDICAL PROFESSION;
PRESCRIPTION;
PRIORITY JOURNAL;
PROFESSIONAL SECRECY;
PSYCHIATRY;
PUBLICATION;
PUBLISHING;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RESEARCH ETHICS;
RETRACTED ARTICLE;
CLINICAL TRIAL (TOPIC);
DEPRESSIVE DISORDER, MAJOR;
ETHICS;
LEGISLATION AND JURISPRUDENCE;
REPRODUCIBILITY;
STANDARDS;
UNITED STATES;
UNIVERSITY;
ANTIDEPRESSIVE AGENTS, SECOND-GENERATION;
CLINICAL TRIALS AS TOPIC;
DEPRESSIVE DISORDER, MAJOR;
HUMANS;
PAROXETINE;
REPRODUCIBILITY OF RESULTS;
RETRACTION OF PUBLICATION AS TOPIC;
UNITED STATES;
UNIVERSITIES;
|
|
EID: 84945911835
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.h4629 Document Type: Article |
|
Times cited : (31)
|
|
References (8)
|
